February 3, 2017
FDA approves Bristol-Myers’s Opdivo for urothelial bladder cancer
U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
February 2, 2017
Eli Lilly keeps Alimta patent in Japan for now, new challenges on the way
Japan IP High Court confirmed validity of Eli Lilly’s Alimta vitamin regimen patents, and has invalidated trials initiated by Sawai regarding Lilly’s vitamin regimen patents for Alimta.
February 2, 2017
MENA biologics industry first ever Biopharma Conference at CPhI Istanbul 2017
With the goal of developing Turkey as an R&D and technology hub, the Government has put place a number of measures to stimulate expansion of biotechnology and biopharmaceutical activities.
February 2, 2017
Pharmapack Europe 2017 Award Winners: Vial injector, pharma compliance pack, smart packaging and autoinjector for prefilled syringes named best innovations
UBM EMEA’s Pharmapack Europe 2017 has named the winners of the 2017 Pharmapack Awards on Wednesday, picking four innovations in the Exhibitor Innovation category, while two winners were chosen to get awards in the Health Product category.
February 2, 2017
NeuroVive to present hepatocellular carcinoma research results at EASL HCC Summit
NeuroVive Pharmaceutical, the mitochondrial medicine company, will present preclinical data from a new generation of sanglifehrin-based compounds with potent inhibitory…
February 2, 2017
Simens Healthcare palces first order from BioPorto
Danish provider of clinical diagnostic tests BioPorto, has finalized a distribution deal with Simens Healthcare for delivery of a NGAL test adapted for Siemens Healthcare BN II and BN ProSpec Systems.
February 2, 2017
Galapagos starts phase II of CF drug testing, opens IND with FDA and triggers $10M payment from AbbVie
Galapagos has started dosing of the first patient with cystic fibrosis (CF) Class III (F508del and a gating mutation like G551D)…
February 2, 2017
Pharnext announces findings evaluating Charcot-Marie-Tooth Neuropathy Score
Pharnext, a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, has announced publication in PLoS One of statistical findings evaluating the clinical scale Charcot-Marie-Tooth Neuropathy Score (CMTNS) for application in Charcot-Marie-Tooth Disease Type 1A (CMT1A).
February 2, 2017
AstraZeneca’s sales drop, expects to launch several new drugs this year
AstraZeneca’s hopes to launch several cancer, respiratory and metabolic diseases drugs, as it expects to see the effects of its long-term growth. The drugmaker nears the end of its patent-expiry period as it expects to bring new medicines to the stores is.
February 2, 2017
Novo Nordisk reports 9% net profit increase
Novo Nordisk has reported net profit increased by 9% to Eur 5,1 billion. Diluted earnings per share increased by 11% to Eur 2,01.